Psagot Investment House Ltd. raised its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 2.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 108,735 shares of the company’s stock after buying an additional 2,121 shares during the quarter. Psagot Investment House Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,705,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Polaris Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 9.0% during the third quarter. Polaris Capital Management LLC now owns 9,911,038 shares of the company’s stock worth $213,484,000 after purchasing an additional 817,964 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in Teva Pharmaceutical Industries by 4.4% during the third quarter. TIAA CREF Investment Management LLC now owns 6,335,449 shares of the company’s stock worth $136,466,000 after purchasing an additional 264,693 shares in the last quarter. Nordea Investment Management AB acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth approximately $2,144,000. Standard Life Aberdeen plc raised its holdings in Teva Pharmaceutical Industries by 9.1% during the third quarter. Standard Life Aberdeen plc now owns 75,392 shares of the company’s stock worth $1,624,000 after purchasing an additional 6,292 shares in the last quarter. Finally, Clearbridge Investments LLC raised its holdings in Teva Pharmaceutical Industries by 2.8% during the third quarter. Clearbridge Investments LLC now owns 1,155,115 shares of the company’s stock worth $24,881,000 after purchasing an additional 31,419 shares in the last quarter. 67.00% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have weighed in on TEVA shares. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a report on Wednesday, January 23rd. Raymond James upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 target price on the stock in a research report on Thursday, February 14th. Piper Jaffray Companies upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $15.00 to $16.00 in a research report on Wednesday, January 23rd. Bank of America restated a “buy” rating and set a $24.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 5th. Finally, Cantor Fitzgerald raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $25.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.53.
In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now directly owns 49,659 shares in the company, valued at approximately $567,105.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Richard Daniell sold 2,098 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $35,414.24. Following the sale, the vice president now owns 2,098 shares in the company, valued at $35,414.24. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,349 shares of company stock worth $384,241. 0.49% of the stock is currently owned by insiders.
NYSE:TEVA traded down $0.32 during midday trading on Wednesday, reaching $11.54. The stock had a trading volume of 10,712,529 shares, compared to its average volume of 11,650,466. Teva Pharmaceutical Industries Ltd has a 12-month low of $11.26 and a 12-month high of $25.96. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The firm has a market cap of $11.70 billion, a price-to-earnings ratio of 4.12, a price-to-earnings-growth ratio of 1.46 and a beta of 1.30.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.38 billion. During the same period last year, the firm posted $0.94 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 15.2% on a year-over-year basis. As a group, analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Growth and Income Funds
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.